Jury awards Puma/Wyeth $107.5M in Tagrisso patent infringement case vs AstraZeneca

PUMA BIOTECHNOLOGY, INC.

Jury found '314 and '162 patents infringed and not invalid; damages $107.5M for past acts.
Puma was dismissed as plaintiff but retains contractual right to recover damages under Pfizer license.
Bench trial on equitable defenses (unclean hands, patent misuse) set for June 17-18, 20, 2024.
Further proceedings will determine ongoing royalty rate through patent term.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.